1. Scrip
  2. >>Conferences
  3. >>J.P. Morgan

Paying For Obesity Drugs: The Looming Affordability Crisis

 
• By Jessica Merrill

As use of new obesity medicines become more widespread, experts at the J.P. Morgan Healthcare conference predicted that paying for them will stress state governments and employers.

money on a scale
Paying for new obesity drugs will be a costly proposition • Source: Shutterstock

Despite the unbridled enthusiasm for new obesity drugs, which are expected to drive pharmaceutical sector growth along with delivering weight loss and related health benefits to patients, paying for the long-term use of the chronic treatments in widespread patient populations is going to present an affordability crisis, experts said at the J.P. Morgan Healthcare Conference.

Key Takeaways
  • Experts at the J.P. Morgan Healthcare Conference discussed the high cost of paying for new obesity drugs and challenges to market access.
  • Medicare, state Medicaid programs and employers will be tested when it comes to paying for more widespread use of the chronic therapies, panelists said

Obesity was a big theme throughout the meeting, held in San Francisco from 8 to 11 January, with nearly every big pharma company admitting it would like to find a way to elbow its way into the therapeutic area currently dominated by

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from J.P. Morgan

BMS Enters A Catalyst-Rich Era Full Of Both LOEs And New Launches

 
• By Mandy Jackson

Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.

Lilly CMO David Hyman On The Company’s Drive To Take ‘Ambitious Swings’ In R&D

 
• By Mandy Jackson

Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.

Momentum In Women’s Health, But Big Obstacles Too

 
• By Jessica Merrill

Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.

Amgen Building On Repatha Experience As It Grows In Cardiovascular, Obesity

 
• By Mandy Jackson

Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.

More from Scrip

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.